FDAnews
www.fdanews.com/articles/149260-soligenix-receives-ind-clearance-from-fda-to-initiate-clinical-program-to-evaluate-sgx203-as-therapy-for-pediatric-crohn-rsquo-s-disease

Soligenix Receives IND Clearance From FDA to Initiate Clinical Program to Evaluate SGX203 as Therapy for Pediatric Crohn’s Disease

September 6, 2012
Soligenix, a development stage biopharmaceutical company, announced that the FDA has completed its review and cleared the IND application for SGX203 (oral beclomethasone 17,21-dipropionate) for the induction treatment of pediatric Crohn’s disease.
Yahoo! Finance